UGT1A4 Polymorphism is not Associated with a Clinically Relevant Change in Giredestrant Exposure.
Vikram MalhiMalgorzata NowickaYa-Chi ChenPriya AgarwalMarie WaldvogelYi Ting Kayla LienMarc HafnerPablo Perez-MorenoHeather M MooreJiajie YuPublished in: Cancer chemotherapy and pharmacology (2024)
Therefore, this study indicates that UGT1A4 polymorphism status is unlikely a clinically relevant factor to impact giredestrant exposure and giredestrant can be administered at the same dose level regardless of patients' UGT1A4 polymorphism status.